Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Conditions
- Lymphoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Renal Cell Cancer
- Recurrent Bladder Carcinoma
- Recurrent Classical Hodgkin Lymphoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Renal Cell Carcinoma
- Stage III Bladder Cancer
- Stage III Lymphoma
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage III Renal Cell Cancer
- Stage III Skin Melanoma
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIA Skin Melanoma
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Bladder Cancer
- Stage IV Lymphoma
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Stage IV Renal Cell Cancer
- Stage IV Skin Melanoma
- Stage IVA Bladder Cancer
- Stage IVB Bladder Cancer
- Unresectable Head and Neck Squamous Cell Carcinoma
- Unresectable Solid Neoplasm
Interventions
- DRUG: Enzyme Inhibitor Therapy
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Nivolumab
- BIOLOGICAL: Pembrolizumab
Sponsor
Rutgers, The State University of New Jersey
Collaborators